Confirms successful performance of its non-invasive sensing
platform in measuring core body temperature and sets the stage for
continued study of the platform’s broad biomarker detection
capabilities
Rockley Photonics (NYSE: RKLY), a global leader in
photonics-based health monitoring and communications solutions,
today announced that the company has successfully completed the
first stages of its preliminary human studies examining the
measurement of core body temperature using its non-invasive
biomarker sensing platform.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211208005704/en/
Comparative Results of Various
Temperature Measurement Methods (Graphic: Business Wire)
In these studies, Rockley researchers have demonstrated that a
photonics-based sensor detecting water spectra in different layers
of the dermis can produce temperature measurements that correlate
more closely with reference sensors for core body temperature than
do auxiliary sensors like oral, ear, and infrared thermometers.
By enabling the detection of core body temperature from a
wearable device such as a smart watch or wristband, Rockley’s
sensing platform has the potential to provide real-time insights
about a variety of health conditions and enable the early detection
of disease states.
Core body temperature is a critical parameter that influences
the body’s regular function and can affect one’s very survival. A
person’s normal temperature can depend on a multitude of factors,
and the human body constantly adapts its temperature to
environmental conditions.
“As consumers and practitioners are becoming increasingly aware
of the importance of monitoring the conditions that contribute to
good health and help identify possible diseases, the ability to
monitor key biomarkers like core body temperature on a continuous
basis will become extremely important,” said Dr. David Klonoff,
clinical professor of medicine at the University of California, San
Francisco. “By miniaturizing the ability to monitor core body
temperature into a tiny form factor, Rockley has effectively paved
the way for a ‘mobile lab’ that people can wear on their wrist.
This will be a game-changer for remote patient monitoring and
should help healthcare providers offer better care for their
patients.”
Because today’s common measurement tools and thermometers are
designed for convenience, they cannot readily measure the
temperature inside the body and therefore may not always reflect
the body’s true core temperature. Rockley’s wearable sensing
platform probes beneath the surface of the skin to measure core
body temperature in a non-invasive and continuous manner.
The Rockley sensing platform uses photonic integrated circuit
(PIC) sensors to generate numerous discrete, narrow-linewidth laser
wavelengths across a wide spectral range. These laser wavelengths
can detect a level of detail beyond today’s LED-based sensors and
are therefore able to discern varying signatures of water
absorption. Rockley’s platform can determine core body temperature
by comparing these signatures to known properties of the water
absorbance spectrum.
“The initial results from these human studies are very
encouraging, and they clearly show how effective our wearable
sensing platform can be for determining core body temperature,”
said Dr. Andrew Rickman, chief executive officer and founder of
Rockley Photonics. “Core body temperature is just one of several
biomarker measurements that our platform will support. We believe
our ongoing human studies will help us optimize algorithms and
refine performance across a broad range of biomarkers, and we look
forward to sharing further positive results in the future. As we
learn more about each biomarker, we expect that the cloud-based
analytics and AI capabilities of our platform can help develop a
more holistic assessment of a person’s health and well-being.”
Rockley’s in-house core body temperature studies represent the
first in a series of studies designed to evaluate and refine the
performance of Rockley’s biomarker sensing platform in measuring a
wide range of biomarkers, including core body temperature, blood
pressure, body hydration, alcohol, lactate, and glucose trends. The
core body temperature studies have been approved by the WIRB –
Copernicus Group Institutional Review Board.
As its platform enhancements are realized, Rockley believes that
its cloud and artificial intelligence (AI) infrastructure can
enable additional capabilities for the fast-growing digital health
domain and help individuals make more informed decisions about
their health and well-being.
Further details about Rockley’s core body temperature studies
have been published in a new whitepaper: Photonics-Based
Measurement of Core Body Temperature, available for download on
Rockley’s website.
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/biomarker-sensing
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “estimate,”
“eventual,” “expand, “expect,” “focus,” “forward,” “future,”
“goal,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,”
“possible,” “position,” “potential,” “predict,” “project,”
“revolutionize,” “seem,” “should,” “trend,” “vision,” “will,”
“would” or other terms that predict or indicate future events,
trends, or expectations, and similar expressions or the negative of
such expressions may identify forward-looking statements, but the
absence of these words or terms does not mean that a statement is
not forward-looking. Forward-looking statements in this press
release include, but are not limited to, statements regarding the
following: (a) the potential of Rockley’s sensing platform to
provide real-time insights about a variety of health conditions and
enable the early detection of disease states by enabling the
detection of core body temperature from a wearable device; (b) the
importance of the ability to monitor key biomarkers like core body
temperature on a continuous basis; (c) the potential impact of the
ability to miniaturize the monitoring of key biomarkers into a tiny
form factor; (d) the ability of the PIC sensors in Rockley’s
sensing platform to detect detail beyond today’s LED-based sensor
technology, discern varying signatures of water absorption, and
determine core body temperature; (e) the potential effectiveness of
the wearable sensing platform for determining core body
temperature; (f) the timing and potential results of Rockley’s
ongoing human studies and the ability of such studies to help
optimize algorithms and refine performance across a broad range of
biomarkers; (g) the expectation that the cloud-based analytics and
AI capabilities of Rockley’s platform can help develop a more
holistic assessment of a person’s health and well-being; (h)
Rockley’s belief that its cloud and AI infrastructure can enable
additional capabilities for the fast-growing digital health domain
and help individuals make more informed decisions about their
health and well-being; (i) the anticipated and potential features,
scope, goals, and benefits of the Company’s platform, products, and
technology; (j) its development of a range of photonic integrated
circuits and associated modules, sensors, and full-stack solutions;
(k) Rockley’s belief that photonics will eventually become as
pervasive as micro-electronics; and (l) Rockley’s potential to
support hyper-scale manufacturing, address a multitude of
high-volume markets, and deliver the complex optical systems
required to bring transformational products to market.
Forward-looking statements are subject to several risks and
uncertainties (many of which are beyond Rockley’s control) or other
assumptions that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the following: (i) Rockley’s ability to achieve
customer acceptance and commercial production of its products and
technology, including in a timely and cost-effective manner; (ii)
Rockley’s ability to achieve customer design wins and convert
memoranda of understanding and development contracts into
production contracts; (iii) risks related to purchase orders,
including the lack of long-term purchase commitments, the
cancellation, reduction, delay, or other changes in customer
purchase orders, and if and to the extent customers seek to enter
into licensing arrangements in lieu of purchases; (iv) Rockley’s
history of losses and need for additional capital and its ability
to access additional financing to support its operations and
execute on its business plan, as well as the risks associated
therewith; (v) legal and regulatory risks; (vi) risks associated
with its fabless manufacturing model and dependency on third-party
suppliers; (vii) Rockley’s reliance on a few significant customers
for a majority of its revenue and its ability to expand and
diversify its customer base; (viii) Rockley’s financial
performance; (ix) the impacts of COVID-19 on Rockley, its customers
and suppliers, its target markets, and the global economy; (x)
Rockley’s ability to successfully manage growth and its operations
as a public company; (xi) fluctuations in Rockley’s stock price and
Rockley’s ability to maintain the listing of its ordinary shares on
the NYSE; (xii) Rockley’s ability to anticipate and respond to
industry trends and customer requirements; (xiii) changes in the
current and future markets in which Rockley is or may be engaged;
(xiv) risks related to competition and intellectual property; (xv)
market opportunity and demand for Rockley’s products and
technology, as well as the customer products into which Rockley’s
products and technology are incorporated; (xvi) risks related to
international operations; (xvii) risks related to cybersecurity,
privacy, and infrastructure; (xviii) risks related to financial and
accounting matters; (xix) general economic, financial, political,
and business conditions, both domestic and foreign; (xx) Rockley’s
ability to realize the anticipated benefits of its recently
completed business combination with SC Health Corporation; and
(xxi) Rockley’s ability to realize the anticipated benefits of
strategic partnerships, as well as other factors described under
the heading “Risk Factors” in Rockley’s quarterly report on Form
10-Q for the quarter ended September 30, 2021, and in other
documents Rockley files with the Securities and Exchange Commission
in the future.
The forward-looking statements contained in this press release
are based on various assumptions, whether or not identified in this
press release, and on Rockley’s current expectations, beliefs, and
assumptions and are not predictions of actual performance. If any
of these risks or uncertainties materialize, or should any of these
assumptions prove incorrect, actual results may differ materially
from those discussed in or implied by these forward-looking
statements. There can be no assurance that future developments
affecting Rockley will be those that have been anticipated. These
forward-looking statements speak only as of the date hereof and
Rockley does not intend to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211208005704/en/
Media Karen Boud Resonates Telephone: +44 1635 898 698 Email:
rockley@resonates.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Rockley Photonics (NYSE:RKLY)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
